Versions

 

2022

Select By Rule or Topic: Download the consolidated index here

Please visit Archive to view marked-up versions and versions that have been superseded or withdrawn.

This section comprises decisions on cases handled by the Listing Committee and/or the Listing Division, to enhance transparency and market understanding of their interpretation of the Listing Rules. Each decision was based on its specific circumstances and is not a precedent for future cases. 

Effective from 1 January 2011, listing decisions will be published under a new naming format as illustrated below:

Before 1 January 2011 On or After 1 January 2011
 
HKEx-LD100-1
HKEx-LD100-2
HKEx-LD101-1
 
HKEx-LD1-2011
HKEx-LD2-2011
HKEx-LD3-2011

Listing decisions published before 1 January 2011 continue to bear the old references.

LD Series Number First
Release
Date (Last
Update
Date)
(mm/yyyy)
Listing Rules/ Topics Particulars
LD138-2022 09/2022 Main Board Rules 8.04, 8A.04 and 19C.02 To provide guidance on why the Exchange considered certain proposed applicants have not demonstrated their suitability to list with a WVR structure
LD137-2022 06/2022 Main Board Rule 7.27B The Exchange was satisfied that there were exceptional circumstances for Company A to undertake the proposed issuance of shares under Rule 7.27B
LD136-2022 06/2022 Main Board Rule 14.06B The Exchange ruled the proposed acquisition to be a reverse takeover
LD135-2022 05/2022
 
Main Board Rule 18A.01 Whether Product X (being one of Company A’s Core Products) which completed the Phase 1 clinical trials under the Therapeutic Goods Administration in Australia and subsequently obtained approval from both the European Medicines Agency and the National Medical Products Administration to commence the global pivotal Phase 2/3 clinical trial satisfies the relevant core product eligibility requirements under GL92-18 and Chapter 18A of the Main Board Rules
LD134-2022 05/2022
 
Main Board Rule 8.04 Whether Company X is suitable for listing in light of (a) the prolonged deterioration of financial performance of its Core Businesses (as defined below); (b) the limited track record of its new services and temporary business improvement; and (c) the failure to prove its business improvement plans
LD133-2022 05/2022 Main Board Rule 8.04 Whether Company X is suitable for listing in light of the material reliance on Dr. A
LD132-2022 05/2022 Main Board Rules 3.08 and 3.09 Whether each of Mr. A and Mr. B is suitable to act as a director of an issuer in light of bribery incidents